Clinical Trial Update: QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FOLFIRI with AMG 479 or AMG 655 versus FOLFIRI alone in KRAS-mutant metastatic colorectal cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• AMG 479
• AMG 655 (AMG-655)

Snippet

Sponsor: NantCell, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED